Bioinformatics Core

生物信息学核心：总结 生物信息学核心将支持WU-PDTC研究项目和核心在其范围内， 计算生物学的需求。我们提出的研究计划涉及算法的许多方面， 计算和信息管理，这需要正式的生物信息学支持， 将结果转化为人体临床试验的建议。生物信息学核心将提供 基础设施，以容纳实验数据和解释工具和人员来分析这些数据。 这些责任分为三个基本类别。这将使基于PDX的方法能够扩展为 在三个重要方面为癌症研究界提供重要的资源：（1）提供统一的，高质量的， 所有WU-PDTC PDX肿瘤模型的蛋白基因组学表征，以供纳入公共领域，（2） 提供PDX模型的治疗反应数据（例如，乳腺、结肠、胰腺和肺）， 具有分子表征和表型反应，其可应用于具有类似 特征，和（3）提供信息和生物统计工具，以支持基于证据的选择， 基于已知的分子和临床数据，为后续的临床试验提供有希望的药物。我们将组织所有 以及所有PDX相关的元数据（例如， 患者和PDX肿瘤、传代和治疗实验数据等），时间序列度量表示 治疗反应等，在我们的WU-PDXdb关系跟踪数据库的扩展中， 融资期。这将支持我们的本地分析和提交义务， 与其他PDTC和PTCCC的整合。这些信息和统计工具将被整合到 PDXNet为未来的临床和临床前试验设计提供了宝贵而持久的资源， 在不同癌症类型中重新利用药物。

BIOINFORMATICS CORE: SUMMARY The Bioinformatics Core will support the WU-PDTC Research Projects and Cores over the spectrum of their computational biology needs. The research program we propose involves many facets of algorithms, computation, and information management, which require formalized bioinformatics support to effectively translate results into recommendations for human clinical trials. The Bioinformatics Core will provide both the infrastructure to house the experimental data and the interpretive tools and personnel to analyze these data. These responsibilities fall into 3 basic categories. This will enable scaling the PDX-based approach into a significant resource for the cancer research community in three important ways: (1) provide uniform, high-quality, proteogenomic characterization for all WU-PDTC PDX tumor models for curation into the public domain, (2) provide therapeutic response data on PDX models (e.g., breast, colon, pancreatic, and lung) including correlation with molecular characterization and phenotypic response that may be applied to other cancer types with similar characteristics, and (3) provide informatic and biostatistical tools to support evidence-based selection of promising agents for subsequent clinical trials based on known molecular and clinical data. We will organize all of this information, as well as all PDX-associated metadata (e.g. molecular and histopathologic data for both the patient and PDX tumors, passages, and therapeutic experimental data, etc.), time series metrics representing treatment responses, etc. in an extension of our WU-PDXdb relational tracking database developed in the prior funding period. This will support both our local analysis and submission obligations and the information integration with other PDTCs and PTCCCs. These informatic and statistical tools will be integrated across the PDXNet to provide a valuable and lasting resource for future clinical and pre-clinical trial designs and possible repurposing of drugs across cancer types.